Cabergoline PCD Pharma Franchise Company

Cafoli Lifecare offers a Cabergoline range of 4 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving gynaecology, endocrinology and IVF prescribers can secure district-wise monopoly franchise rights for this specialised dopamine agonist with full promotional support.

What is Cabergoline?

Cabergoline is a long-acting dopamine D2 receptor agonist that suppresses secretion of the hormone prolactin from the pituitary gland. It is used to treat disorders of high prolactin (hyperprolactinaemia), including prolactin-secreting pituitary tumours, and to stop or prevent breast-milk production when required. Reference: PubChem - Cabergoline.

Available Forms

The Cafoli Cabergoline portfolio is offered as oral Tablets in the commonly prescribed strengths for once- or twice-weekly dosing. Contact us for current pack presentations and trade offers.

Therapeutic Applications

Cabergoline is prescribed for hyperprolactinaemia, prolactinomas, prolactin-related infertility and menstrual disturbance, and for suppression or inhibition of lactation. Prescribers include gynaecologists, endocrinologists, reproductive-medicine and IVF specialists and neurophysicians.

Why Cabergoline is a High-Potential Molecule for Distributors

Cabergoline is a niche, specialist-driven molecule with limited PCD competition, and demand is rising with the growth of infertility and IVF practice where prolactin control is routine. Because it is a defined, higher-value tablet prescribed for extended courses by loyal specialist prescribers, it offers distributors healthy margins and a differentiated addition to a gynae-endocrine range.

Why Choose Cafoli Lifecare

Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.

References

1. PubChem: Cabergoline
2. MedlinePlus: Cabergoline
3. PubMed: cabergoline in hyperprolactinaemia